Clinical Study | Office of Clinical Research

Alector Study

Posted Date: May 29, 2020

Investigator: Russell Sawyer
Specialties:
Type of Study: Drug

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations inthe Progranulin Gene

Criteria:

Please Contact The Study Contact For Further Details On The Eligibility Criteria

Keywords:

Frontotemporal Dementia, Dementia, Heterozygous Mutation

For More Information:

Kayla Stallworth
513-558-1707
stallwkj@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List